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Background: While prophylactic human papilloma virus (HPV) vaccination is considered effective in young girls, it
is unclear whether a catch-up vaccination of older girls would be beneficial. We, therefore, aimed to examine the
potential health impact of a HPV catch-up vaccination of girls who were too old at the time of vaccine introduction,
hence aged 16 and older.
Methods: We systematically searched the literature for randomized clinical trials (RCTs) that examined the effect of
HPV vaccines on overall mortality, cancer mortality and incidence, high-grade cervical intraepithelial neoplasia grade
2 and higher (CIN2+), vulvar intraepithelial neoplasia (VIN) and vaginal intraepithelial neoplasia (VaIN) grade 2 and
higher lesions (VIN2+ and VaIN2+, respectively) genital warts (condyloma). We considered all lesions and those
associated with HPV type(s) included in the vaccines. RCTs reporting on serious adverse events were also eligible.
Selected publications were assessed for potential risk of bias, and we ascertained the overall quality of the evidence
for each outcome using Grading of Recommendations Assessment, Development and Evaluation (GRADE).
Meta-analyses were performed, assuming both random and fixed effects, to estimate risk ratios (RR) and
corresponding 95% confidence intervals (CI), using intention-to-treat and per-protocol populations.
Results: We included 46 publications reporting on 13 RCTs. Most of the RCTs had a maximum follow-up period of
four years. We identified no RCT reporting on the effect of HPV catch vaccination on overall and cancer related
mortality, and on cervical cancer incidence. We found a borderline protective effect of a HPV catch-up vaccination
on all CIN2+, with a pooled RR of 0.80 (95% CI: 0.62-1.02) for a follow-up period of 4 years. A HPV catch-up
vaccination was associated with a reduction in VIN2+ and VaIN2+ lesions, and condyloma. No difference in risk of
serious adverse events was seen in vaccinated participants versus unvaccinated women (pooled RR of 0.99 (0.91-1.08)).
Conclusions: This systematic review indicates that a HPV catch-up vaccination could be beneficial, however the
long-term effect of such a vaccination, and its effect on cervical cancer incidence and mortality is still unclear.
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Human papillomavirus (HPV) is considered the most
common sexually transmitted agent worldwide [1], and
most sexually active women and men will experience an
HPV infection during their lifetime [2]. More than 100
types of HPV have been identified [3,4]. However, a
small number of HPV types contribute to a large pro-
portion of HPV-related diseases. Most HPV infections
resolve within 1-2 years [4], but some are persistent and
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unless otherwise stated.and for its precursor lesions [4,5]. Approximately 70% of
cervical cancers in the world are attributed to two of the
most common HPV types, 16 and 18 [4,6,7]. The World
Health Organisation (WHO) International Agency for Re-
search on Cancer judged that there was sufficient evidence
to support a causal role of HPV 16 infection in carcinoma
of the cervix, vulva, vagina, penis, anus, oral cavity, and
oropharynx and tonsil [8]. The evidence was also judged
sufficient to recognize a causal role of HPV types 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, and 59 in cervical cancer [8].
It was estimated that 5.2% of all cancers worldwide are at-
tributed to HPV infections [7]. Genital warts have been
linked to HPV infection [9], with approximately 100% oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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HPV 6 or 11 [10]. An increasing incidence of genital warts
has been described over recent decades in Europe [11].
Efficient prophylactic vaccines could have an import-
ant public health impact [12]. Since 2006, two vaccines
(Cervarix and Gardasil) have been licensed for girls aged
9 to 26, and through age 45 years in some countries
[13], and have been introduced in the childhood immun-
isation programme in many countries for girls aged 9 to
18 [14]. While prophylactic HPV vaccination has been
shown to be effective in young girls, it is still unclear
whether a catch-up vaccination of girls who were too
old at time of vaccine introduction would be beneficial.
To the best of our knowledge, three meta-analyses
have been published to date and they reported results on
the effect of HPV vaccination of older girls on persistent
HPV infection [15], and only on outcomes associated
with the HPV types included in HPV vaccines [16,17]. In
this systematic review, we present results on prevention
of all lesions regardless of the HPV status of the lesions.
This is an appropriate measure of the public health im-
pact of a HPV catch-up vaccination, as it estimates more
accurately the expected reduction in total disease burden
after implementation of such a vaccination program.
In this article, we present a systematic review of the
international literature to investigate the health impact
of a HPV catch-up vaccination of girls who were too old
at the time of vaccine introduction. Taking into account
the age range covered by HPV vaccines licensing, and
the age at introduction of HPV vaccination in different
countries, we have therefore examined the health impact
of HPV vaccination of girls aged 16 and older.Methods
Eligibility criteria
We included randomised clinical trials (RCT) that ex-
amined the efficacy of a HPV catch-up vaccination of
young women aged 16 and older. Eligible RCTs exam-
ined the effect of HPV vaccines on overall mortality,
cancer related mortality, cervical cancer, high-grade cer-
vical intraepithelial neoplasia grades 2 and higher (CIN2+),
vulvar intraepithelial neoplasia (VIN) and vaginal
intraepithelial neoplasia (VaIN) grade 2 and higher lesions
(VIN2+ and VaIN2+, respectively), and genital warts
(condyloma). RCTs investigating HPV vaccination safety
and reporting on serious adverse events were also eligible.
RCTs that used the following comparison groups were
included: HPV vaccine against placebo, HPV vaccine
against placebo with in addition another vaccine (such as
hepatitis B vaccine) used in the intervention and in the
placebo groups, or RCTs comparing two different HPV
vaccines. No language restriction was applied during the
literature search.The literature search
We systematically searched several databases from 1999
up to October 2012 (Ovid MEDLINE(R) In-Process &
Other Non-Indexed Citations, Ovid MEDLINE(R), Embase,
Cochrane Central Register of Controlled Trials, ISI web
of Science, PubMed, and Google scholar). Details of
the search strategy are provided in the Additional file 1:
Appendix. Furthermore, we contacted the pharmaceut-
ical companies with marketing authorization for HPV
vaccines in Norway (GlaxoSmithKline AS and Sanofi
Pasteur MSD) to obtain additional relevant information.
The search was supplemented with papers found in
bibliographies of selected articles. We used a search fil-
ter to select only RCTs.Examined outcomes
To assess the potential health impact of a HPV catch-up
vaccination, we have examined several outcomes. We
planned to investigate the effect of a HPV catch-up vac-
cination on overall and cancer mortality, and on cervical
cancer incidence. Furthermore, we aimed to examine
several female genital HPV related diseases and investi-
gate the association between HPV vaccination and these
outcomes. These outcomes were CIN2+, VIN2+, VaIN2+
and genital warts (condyloma acuminata). We also ex-
amined the association between HPV vaccination and
these lesions considering only HPV related lesions (i.e.
HPV type(s) found in the lesion is/are the HPV type(s)
covered by the examined vaccine).
We examined also adverse events possibly linked to HPV
vaccination. We considered only adverse events reported
as serious adverse events in the included publications.Data extraction and quality assessment
The selection of articles was carried out by two of the
review authors (divided among EC, LJ and IS). All titles
and abstracts from the reference lists of articles were
screened, and full-text articles were retrieved for pub-
lications judged potentially relevant. Each full-length
article was assessed for possible inclusion according to
the predefined eligibility criteria. Potential disagreements
were resolved by discussion with a review author.
Selected publications were assessed for potential risk
of bias according to the Cochrane risk of bias tool [18].
All assessments were performed and agreed upon by
two of the review authors. No studies were excluded on
the basis of high risk of bias.
One review author extracted the data and another veri-
fied the information. When data were reported in several
publications, we used the publication with the longest
follow-up period. If a publication included several trials,
preference was given to the publication that included the
most trials. We extracted detailed data on characteristics
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vaccine and control, and on relevant outcomes.
Two review authors assessed the overall quality of the
evidence for each selected outcome using GRADE (Grading
of Recommendations Assessment, Development and
Evaluation) [19].
Statistical analyses
When possible, we carried out meta-analyses to investigate
the association between HPV vaccination and outcomes
described above, comparing vaccine and control groups.
Extracted data were pooled together by performing meta-
analyses using the Review Manager software (RevMan).
When the outcome data could not be pooled in meta-
analyses, we described the results in a narrative manner.
Random and fixed effect models were used to calculate
pooled risk ratios (RR) and corresponding 95% confidence
intervals (CI). If we identified fewer than three studies
reporting data on the same clinical outcome, we report
pooled estimates using fixed effect models. Otherwise,
pooled estimates obtained with random effect models
are presented.Records idenﬁed through 
database searching 
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Figure 1 Selection process of randomized control trials.We performed intention-to-treat (ITT) analyses. How-
ever, none of the included studies used an intention-to-
treat population including only randomized subjects.
We, therefore, used the modified intention-to-treat pop-
ulations as defined in the included publications. The
modified ITT population was most commonly defined
as participants who received at least one vaccine or con-
trol dose and had at least one follow-up visit post-dose
1. When possible, we conducted also analyses according
to per-protocol-population (PPP). The PPP typically in-
cluded participants who received the three vaccine or
control doses. We pooled results published for the safety
population, using estimates reported for the longest
follow-up period in each study. In most trials, the safety
population was similar to the modified ITT population.
Results
Literature search and characteristics of included studies
The study selection process is presented in Figure 1. The
literature search retrieved 616 references. In addition,
we received 12 references from the pharmaceutical com-
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were selected.
Characteristics from included studies [20-40] are pre-
sented in Table 1. Totally, the studies included nearly 40
000 participants. They were conducted in North America
(USA and Canada), South America, Europe and Asia.
Most clinical trials had a maximum follow-up period of
4 years, with two reporting results after a follow-up of 6
[36], and 8 years [22]. The participants were healthy and
non-pregnant women aged 15 to 45 years of age. One of
the studies included women aged 9 to 23 years, but the
mean age was 17 years [41]. The FUTURE (protocol 19)
trial included women aged 24 to 45 (mean age 34 years)
[29,30]. However, we included this study since one of our
inclusion criterion was women aged 16 and older. Some
studies included only participants with no history of HPV
infection and negative HPV tests at entry into the study
[34], but most studies recruited participants with fewer
than four to six lifetime sex partners [21,34,41,42].
Vaccines used in the trials were the bivalent vaccine
containing HPV 16 and 18 virus-like particles (VLP) from
GlaxoSmithKline, or the monovalent vaccine containing
HPV 16 VLP and the quadrivalent vaccine containing
HPV 6, 11, 16 and 18, both from Sanofi Pasteur MSD. All
trials used placebo as comparator except for two studies:
one used hepatitis B vaccine in both the intervention and
the control groups [43], and one compared the bivalent
and the quadrivalent vaccines [44]. All vaccines were given
as three doses during a six months period (at day 1,
months 2 and 6; or at months 0, 1 and 6).
Some of the included studies had unclear allocation
concealment and unclear blinding. However, all studies
were assessed as having low risk of bias.
While, one of our aims was to investigate the effect of
a HPV catch-up vaccination on overall and cancer re-
lated mortality, and on the incidence of cervical cancer,
no RCT examining these outcomes were identified.
Effect of HPV vaccines on outcomes identified in relevant
studies
Table 2 summarises the effects of HPV vaccine versus pla-
cebo or no vaccine and the quality of evidence for each
outcome.
Overall mortality
Overall mortality was seldom reported, and primarily only
in the text. Overall mortality was reported in 7 RCTs
[28,29,32,34,41,45]. The authors reported that none of the
recorded deaths were considered to be related to the inter-
vention in the vaccine or control groups.
CIN2+
The intention-to-treat (ITT) analysis based on five stud-
ies showed a borderline statistically significant reductionin CIN2+ lesions associated with HPV vaccination with
a pooled RR of 0.80 (95% CI: 0.62-1.02) for a follow-up
period of 4 years (Figure 2). The quality of the evidence
was judged moderate. Two of the included studies pub-
lished results for longer follow-up periods, and reported
RRs of 0.29 (0.11-0.78) [36], and 0.64 (0.27-1.52) [22]
for follow-up of 6 and 8 years, respectively (results not
shown).
The reported RR using the per protocol population
(PPP) showed a non statistically significant reduction for
all CIN2+ lesions after a four year follow-up period (RR:
0.49; 95% CI: 0.21-1.14) (Figure 2). However, this finding
was based on only one RCT, and the quality of the evi-
dence was considered low.
When considering only CIN2+ HPV related lesions,
we found statistically significant reductions in risk with
HPV vaccination both for studies using ITT and PPP
populations (Figure 3). The pooled RRs were 0.54 (0.44-
0.67) for the ITT population, and 0.05 (0.01-0.16) for the
PPP population, both for a 4 years follow-up period. The
quality of the evidence was considered high for both es-
timates. Two studies reported data for 721 participants
from the ITT population for 8 years follow up (Figure 3).
The pooled RR was 0.29 (0.09-0.96). The quality of the
evidence for this outcome was considered moderate.
VIN2+, VaIN2+
We found a statistically significant reduction in risk of all
VIN2+ or VaIN2+ lesions with HPV vaccination (RR =
0.49; 95% CI = 0.32-0.76) based on two RCTs reported in
one publication (Figure 4). The quality of the evidence for
this outcome was considered moderate. However, when
considering only published estimates on HPV related
VIN2+ or VaIN2+ (from four studies), the reduction in
risk was not statistically significant (pooled RR = 0.72;
0.03-15.02) (Figure 4). The quality of the evidence for this
outcome was low.
Condyloma acuminata
HPV vaccination was associated with a reduction in risk
of condyloma, both for all condyloma and for those re-
lated to HPV types included in HPV vaccines in the ITT
population (Figure 5). The reported RR, based on two
RCTs, was 0.38 (0.31- 0.47) for all condyloma, and the
pooled RR was 0.28 (0.12-0.65) for HPV related condyl-
oma. The quality of the evidence for these two outcomes
was high.
Serious adverse events
We included 14 studies that reported estimates of the as-
sociation between HPV vaccination and serious adverse
events. The risk of having a serious adverse event was
similar in both the vaccine and control groups (Figure 6).
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Table 2 Summary of findings table for HPV vaccine versus placebo or no vaccine













CIN 2+ ITT (any HPV type)
(4-year follow-up)
51 per 1000 41 per 1000 (32 to 52) RR 0.8 (0.62 to 1.02) 39381 (5 studies) ⊕⊕⊕⊝ moderate1,2
CIN2+ PPP (any HPV type)
(4-year follow-up)
29 per 1000 14 per 1000 (6 to 34) RR 0.49 (0.21 to 1.14) 1096 (1 study) ⊕⊕⊝⊝ low2,3
CIN2+ ITT (any HPV type)
(6-year follow-up)
34 per 1000 10 per 1000 (4 to 27) RR 0.29 (0.11 to 0.78) 1002 (1 study) ⊕⊕⊕⊝ moderate2,4
CIN2+ ITT (any HPV type)
(8-year follow-up)
85 per 1000 54 per 1000 (23 to 128) RR 0.64 (0.27 to 1.52) 290 (1 study) ⊕⊕⊝⊝ low2,5,6
CIN2+ lesions ITT (HPV 16 and/or
18 related) (4- year follow up)
22 per 1000 12 per 1000 (10 to 14) RR 0.54 (0.44 to 0.67) 42652 (7 studies) ⊕⊕⊕⊕ high2
CIN2+ ITT (HPV 16 and/or
18 related) (8-year follow-up)
31 per 1000 9 per 1000 (3 to 30) RR 0.29 (0.09 to 0.96) 721 (2 studies) ⊕⊕⊕⊝ moderate4,7
CIN2+ PPP (HPV (16 and/or 18 related)
(4- year follow up)
11 per 1000 1 per 1000 (0 to 2) RR 0.05 (0.01 to 0.16) 35023 (6 studies) ⊕⊕⊕⊕ high2
Genital warts ITT (any HPV type)
(4-year follow-up)
40 per 1000 15 per 1000 (13 to 19) RR 0.38 (0.31 to 0.47) 17391 (2 studies) ⊕⊕⊕⊕ high2
Genital warts ITT (HPV 6 and/or 11
related) (4-5 year follow up)
30 per 1000 8 per 1000 (4 to 19) RR 0.28 (0.12 to 0.65) 21686 (4 studies) ⊕⊕⊕⊕ high2
VIN2+ and VaIN2+ ITT (any HPV type)
(4-year follow-up)
7 per 1000 3 per 1000 (2 to 5) RR 0.49 (0.32 to 0.76) 17391 (2 studies) ⊕⊕⊕⊝ moderate2,4
VIN2+ and VaIN 2+ ITT (HPV related)
(4-5-year follow-up)
4 per 1000 3 per 1000 (0 to 60) RR 0.72 (0.03 to 15.02) 21694 (4 studies) ⊕⊕⊝⊝ low1,6
Serious Adverse Events (Follow-up:
>7 months8, longest reported follow up)
44 per 1000 44 per 1000 (40 to 48) RR 0.99 (0.91 to 1.08) 43342 (14 studies) ⊕⊕⊕⊝ moderate2,9
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI Confidence interval, RR Risk ratio;
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
&No studies that reported on overall and cervical cancer mortality, and cervical cancer incidence were identified.
1I-square >75%.
2Funded by vaccine provider (we did not downgrade).
3Few events, high number of loss to follow-up.
4Few events.
5Participants were not blinded in this extended follow-up study.
6Few events and wide confidence interval. Both estimates of relative and absolute effects have wide confidence intervals.
7Participants were not blinded in one of the extended follow-up studies.
8We used the longest reported follow-up for each trial.
9We have reported the results for the safety population as it was defined in each of the studies. Might have led to uncertain loss to follow up. Serious adverse
events are defined differently in the studies.
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evidence for this outcome was moderate.
We identified one publication that compared the bi-
valent vaccine with the quadrivalent vaccine, and exam-
ined possible differences safety between these two vaccines
[44]. However, the quality of the evidence was judged low,
and no statistically significant difference was found (RR =
1.05; 95% CI: 0.59-1.05) (results not shown).Discussion
This systematic review shows that there is a protective
effect of HPV vaccination against CIN2+ lesions associ-
ated with the HPV types included in HPV vaccines, all
VIN2+ and VaIN2+, and condyloma acuminate (HPV
related and not). The results also indicate a protective
effect against all CIN2 lesions (HPV associated and
not). No difference in the occurrence of serious adverse
Study or Subgroup
FUTURE (protocol 19)
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0.49 [0.21, 1.14]
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HPV vaccine Control Risk Ratio Risk Ratio
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0.01 0.1 1 10 100
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Figure 2 Risk of cervical intraepithelial neoplasia grade 2 and higher lesions associated with HPV vaccination.
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to control groups.
High grade cervical lesions (CIN2+) were proposed by
the WHO as an appropriate surrogate outcome for RCTs
examining the effect of HPV vaccination [46]. A reason for
this was that since screening for cervical cancer is available,
conducting RCTs considering cervical cancer as main out-
come would be unethical. CIN lesions are precursors of in-
vasive cervical cancer and while most lower grade CIN (i.e.
CIN1) regress spontaneously to normal, a higher percent-
age of CIN2+ become malignant making these lesions a
more appropriate outcome to examine [47]. However, when
investigating HPV vaccination efficacy, the main outcome
of interest remains cervical cancer, and CIN2+ lesions are
mainly examined to extrapolate on the possible effect of
HPV vaccination on cervical cancer. One should be cau-
tious when interpreting results on CIN2+ lesions on the
possible effect of HPV vaccination on cervical cancer risk.
For example, differing results for cervical cancer than those
published up to date on precursor lesions could be ex-
pected if the HPV types involved in precursor lesions were
different to those related to cervical cancer. A meta-analysis
reported that while HPV 16 and 18 are the two most com-
mon types both in high-grade squamous intraepithelial le-
sions (HSIL) and squamous cell carcinoma of the cervix(SCC), these HPV types were reported to be more common
in SCC than in HSIL with prevalence ratios of 1.21 (95%
CI: 1.16-1.26), and 1.79 (1.56-2.10) for HPV 16 and 18, re-
spectively [48]. It is, therefore, possible that higher protect-
ive effect of HPV vaccination would be found for HPV
related cervical cancers compared to precursor lesions.
HPV vaccines were shown to be highly efficacious to pre-
vent persistent infections with HPV [16,17,49,50]. Previous
meta-analyses have presented results only for persistent
HPV infection, and pre-cancerous lesions or condyloma
associated with HPV types covered by the vaccines [16,17].
To the best of our knowledge, our systematic review is the
first to present the effect of HPV catch-up vaccination on
all pre-cancerous lesions and condyloma, considering both
all lesions and those associated with particular HPV types.
Examining the effect of HPV vaccination on relevant out-
comes regardless of these being related to any HPV type
enables a more accurate estimate of the total disease reduc-
tion that could be expected after vaccination. We found a
borderline statistical significant protection of a HPV catch-
up vaccination on all CIN2+ lesions. While 4 out of 5 in-
cluded RCTs found a protective effect of HPV vaccination
on all CIN2+ lesions, one trial reported a non statistically
significant increased risk associated with HPV vaccination
(RR: 1.21, 95% CI: 0.84-1.75). Participants of this study
Study or Subgroup
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Figure 3 Risk of HPV related cervical intraepithelial neoplasia grade 2 and higher lesions associated with HPV vaccination.
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http://www.biomedcentral.com/1471-2458/14/867were older than those from other studies (age range: 24 to
45, mean age 34 years), and somewhat older than
women who would most commonly be targeted by a
catch-up vaccination. Observational studies examining
early vaccine impact have shown a decline in high-grade
cervical lesions [51].
While HPV types 16 and 18 are the two most com-
mon HPV types worldwide, prevalence of HPV types dif-
fers geographically [1]. In included trials, participants
are from different geographical regions. They are for ex-
ample, from Northern America where HPV 16 and 53
are the two most common HPV types, or from Southern
America were HPV16 and 58 are the most prevalent
types [1]. When ascertaining HPV vaccination efficacy
using CIN2+ regardless of the lesions being related to
HPV types, differing results may be found according to
how common the HPV types included in the vaccine(s)
are in the geographical area of interest. In regions werethe most common HPV types are included in the vac-
cine, like in Northern Europe where HPV 16 and 18 are
the two most common types, one could expect a stron-
ger protective effect of HPV vaccination on all CIN2+ le-
sions than in areas where other HPV types are more
frequent.
While prophylactic HPV vaccination is considered ef-
fective and cost-effective in young girls, it is unclear
whether a catch-up vaccination of older girls would have
beneficial effect on health outcomes. This is primarily due
to differences of HPV status between young and older
girls, with younger more likely to be free of HPV infection.
In the population included in this systematic review, the
HPV status of participants varies, because of the age-range
examined in this review, and differences in studies inclu-
sion criteria: Some studies included only participants with
no history of HPV infection and negative HPV tests at
entry into the study [34], and other studies recruited
Study or Subgroup
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Figure 4 Risk of vulvar and vaginal intraepithelial neoplasia lesions associated with HPV vaccination. Legend: VIN2+: vulvar and vaginal
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http://www.biomedcentral.com/1471-2458/14/867participants with fewer than four to six lifetime sex part-
ners [21,34,41,42]. The population considered in this sys-
tematic review is, therefore, representative of a population
targeted by a HPV catch-up vaccination that would be
composed of girls both HPV naïve and not. Possible differ-
ences in HPV vaccination of young women compared to
older women could, also, be explained by potential differ-
ences in HV distribution by age [52]. Brotherton et al.Figure 5 Risk of condyloma associated associated with HPV vaccinatireported that HPV type 16 was more prevalent among
younger women [52].
The conducted RCTs on the efficacy of HPV vaccin-
ation have a relatively short follow-up period with most
results published up to date based on follow-up periods
of approximately four years. Two included trials pub-
lished results after longer follow-up periods (6 and
8 years) but the results were based on few participantson in girls aged 16 and older.
Bhatla et al
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Figure 6 Risk of serious adverse events associated with HPV vaccination in girls aged 16 and older.
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http://www.biomedcentral.com/1471-2458/14/867and are inconclusive [22,36]. The evidence published so
far does not allow us to conclude on the long term effect
of HPV vaccination. Furthermore, as cancer takes a long
time to develop, longer follow-up periods are required to
ascertain the efficacy of HPV vaccination in preventing
cervical cancer. The use of population-based registries was
described as the best study design to answer this question,
and preliminary observations suggested that results on
vaccine efficacy against cervical cancer could be available
within the next 5 to 10 years [53]. Furthermore, due to
lack of long follow-up periods of RCTs published to date,
the durability of immune response to HPV vaccines is un-
known. Further investigation is, therefore, needed to
examine whether booster vaccination(s) would be required
after initial vaccination.
In most developed countries, national cervical cancer
screening programs have been implemented, with a re-
ported reduction in cervical cancer incidence probably
partly due to these programs [54-56]. A public health pol-
icy aiming at implementing a HPV vaccination should be
done considering the interconnection between the HPV
vaccination program and the cervical cancer screening
program. While HPV vaccination could present a valuable
primary prevention for cervical cancer and other HPV re-
lated diseases, certain gaps need to be addressed. Although
cross-protection against other HPV types than those cov-
ered by the vaccines is possible [57], the two vaccines used
nowadays do not protect against all HPV types. HPV type
replacement following HPV vaccination has also been a
discussed issue [58,59]. However, up to date, it is not clear,
whether there will be an increase of HPV types that havealso been linked to cancer but not present in HPV vac-
cines [60]. Lower coverage could be possible for a catch-
up vaccination strategy compared to vaccination of the
primary target population of young girls recruited, for ex-
ample, through schools (i.e. 9-13 years old). Finally, while
long term efficacy of HPV vaccines is unproven to date,
such an efficacy is required to prevent cervical cancer. A
good secondary prevention, such as cervical cancer
screening programs, could cover these potential gaps in
HPV vaccination. However, concerns have been raised on
the possible future consequences of HPV vaccination on
the attendance at the cervical cancer screening programs,
with possible lower compliance among vaccinated women
who perceived themselves at lower risk of cervical cancer
[61,62]. Furthermore, since this systematic review indi-
cates a protective effect of HPV vaccination on all CIN2+
lesions, we could therefore foresee a decrease in screening
referrals and subsequent treatments of pre-malignant le-
sions in the future. The current evidence points towards
the need of coordinated policies for HPV vaccination and
cervical cancer screening [63,64].
The evidence, to date, shows that a HPV catch-up vac-
cination can be considered safe, with no differences seen
in serious complications between the vaccination and
the control groups. However, the number of cases of
published clinical studies may not be sufficient to deter-
mine the occurrence of rarely occurring (severe) adverse
events in a reliable way. Furthermore, due to the rela-
tively short follow-up period since HPV vaccination im-
plementation in different countries, the long-term safety
of the vaccines is unclear and needs to be further
Couto et al. BMC Public Health 2014, 14:867 Page 12 of 14
http://www.biomedcentral.com/1471-2458/14/867monitored in future studies. While different adverse
events have been reported, as we examined only events re-
ported as serious this ensures a better homogeneity of the
ascertained outcome across studies.
Conclusions
This systematic review indicates that HVP catch-up vaccin-
ation could be a valuable primary prevention against cervical
cancer and national catch up vaccination programs have
already been implemented in several countries. However, the
long term effect of such a vaccination strategy and its impact
on cervical cancer prevention remains to be determined.
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